JP Morgan Chase
ACOR

JP Morgan Chase’s Acorda Therapeutics ACOR Stock Holding History

JP Morgan Chase’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4
Closed -$50 – 7905
2024
Q1 		$50 Buy
4
+1
+33% +$15 ﹤0.01% 7041
2023
Q4 		$44 Buy
3
+1
+50% +$11 ﹤0.01% 7223
2023
Q3 		$29 Buy
2
+1
+100% +$15 ﹤0.01% 7100
2023
Q2 		$13 Hold
1
– – ﹤0.01% 6810
2023
Q1 		$0 Hold
1
– – ﹤0.01% 7432
2022
Q4 		$0 Hold
1
– – ﹤0.01% 7220
2022
Q3 		$0 Hold
1
– – ﹤0.01% 7037
2022
Q2 		$0 Buy
+1
New +$18 ﹤0.01% 7083
2022
Q1 		– Hold
0
– – – 7187
2021
Q4 		– Hold
0
– – – 7121
2021
Q3 		– Hold
0
– – – 6949
2021
Q2 		– Hold
0
– – – 6717
2021
Q1 		– Hold
0
– – – 6467
2020
Q4 		– Sell
-21
Closed -$1.93K – 6045
2020
Q3 		$1K Buy
21
+8
+62% +$603 ﹤0.01% 5428
2020
Q2 		$1K Sell
13
-4,481
-100% -$474K ﹤0.01% 5318
2020
Q1 		$502K Buy
4,494
+2,721
+153% +$536K ﹤0.01% 3814
2019
Q4 		$434K Sell
1,773
-112
-6% -$28.3K ﹤0.01% 4307
2019
Q3 		$649K Sell
1,885
-119
-6% -$64.7K ﹤0.01% 4062
2019
Q2 		$1.78M Sell
2,004
-19
-0.9% -$23.3K ﹤0.01% 3470
2019
Q1 		$3.23M Sell
2,023
-33
-2% -$59.5K ﹤0.01% 2960
2018
Q4 		$3.84M Sell
2,056
-51
-2% -$111K ﹤0.01% 2785
2018
Q3 		$4.97M Sell
2,107
-504
-19% -$1.56M ﹤0.01% 2749
2018
Q2 		$8.99M Sell
2,611
-895
-26% -$2.74M ﹤0.01% 2231
2018
Q1 		$9.95M Sell
3,506
-1,364
-28% -$4.08M ﹤0.01% 2035
2017
Q4 		$12.5M Buy
4,870
+343
+8% +$975K ﹤0.01% 1937
2017
Q3 		$12.7M Buy
4,527
+1,705
+60% +$4.49M ﹤0.01% 1813
2017
Q2 		$6.67M Buy
2,822
+32
+1% +$63.4K ﹤0.01% 2274
2017
Q1 		$7.03M Buy
2,790
+383
+16% +$1.1M ﹤0.01% 2185
2016
Q4 		$5.43M Sell
2,407
-77
-3% -$183K ﹤0.01% 2386
2016
Q3 		$6.22M Sell
2,484
-43
-2% -$128K ﹤0.01% 2094
2016
Q2 		$7.73M Buy
2,527
+927
+58% +$3.01M ﹤0.01% 2005
2016
Q1 		$5.08M Sell
1,600
-350
-18% -$1.45M ﹤0.01% 2210
2015
Q4 		$10M Sell
1,950
-263
-12% -$1.15M ﹤0.01% 1825
2015
Q3 		$7.04M Buy
2,213
+20
+0.9% +$77.6K ﹤0.01% 2006
2015
Q2 		$8.77M Buy
2,193
+787
+56% +$3.04M ﹤0.01% 2009
2015
Q1 		$5.61M Buy
1,406
+1,140
+429% +$5.22M ﹤0.01% 2270
2014
Q4 		$1.3M Sell
266
-27
-9% -$116K ﹤0.01% 3213
2014
Q3 		$1.19M Buy
293
+20
+7% +$75K ﹤0.01% 3222
2014
Q2 		$1.1M Buy
+273
New +$1.11M ﹤0.01% 2813
2014
Q1 		– Sell
-397
Closed -$1.39M – 4008
2013
Q4 		$1.39M Sell
397
-3,984
-91% -$15.5M ﹤0.01% 2973
2013
Q3 		$18M Sell
4,381
-434
-9% -$1.87M 0.01% 1390
2013
Q2 		$19.1M Buy
+4,815
New +$19.8M 0.01% 1282

Other funds holding ACOR

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

JP Morgan Chase's ACOR Position: Q2 2024 in Review

JP Morgan Chase sold out of Acorda Therapeutics (ACOR) in Q2 2024, closing a stake of 4 shares — an estimated $50 sold.

JP Morgan Chase first reported a position in ACOR in Q2 2013 and held it in 37 quarters. The position peaked at $19.1M in Q2 2013. 2 funds tracked by Wall St. Rank hold ACOR as of Q2 2024.

  • JP Morgan Chase reported no remaining Acorda Therapeutics position as of Q2 2024 after selling out during the quarter.
  • JP Morgan Chase sold 4 Acorda Therapeutics shares in Q2 2024, an estimated $50.
  • JP Morgan Chase first reported a position in Acorda Therapeutics in Q2 2013 and held it in 37 quarters.
  • JP Morgan Chase's Acorda Therapeutics position peaked at $19.1M in Q2 2013.
  • 2 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2024.

Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.